-
Global Biotechnology & Pharmaceutical Markets4 weeks agoWebinar for Stakeholder Engagement on the New Final Guideline on General Principles for Model-Informed Drug Development (ICH M15) – 10/29/2026
Adopted by the International Council for Harmonisation (ICH) in February 2026, the new ICH M15 guideline, “General Principles for Model-Informed Drug Development,” provides general recommendations for...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoNovartis taps China’s Abogen for autoimmunity TCE
Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoUK puts £80m behind dementia diagnosis push
The UK is putting £80 million ($105 million) in funding behind nine technologies that it hopes will be able to diagnose dementia more quickly.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoChina biopharma still faces a long road to globalization
BIOCENTURY | GUEST COMMENTARYCHINA BIOPHARMA STILL FACES A LONG ROAD TO GLOBALIZATIONChinese science is already flowing out of the Oktagon. Chinese companies are not. Can this...
-
Global Biotechnology & Pharmaceutical Markets4 weeks ago3 takeaways from a European obesity scientific meeting
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: A journey to witness China’s biotech boom up close
Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making...
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
A final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoGLOBE model finalised, with narrowed scope and fewer savings
CMS has finalised a new drug pricing policy for Medicare that has drawn sharp criticism from the pharma industry.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoSTAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.
-
Global Biotechnology & Pharmaceutical Markets4 weeks agoLive from Amsterdam: Grand Rounds Europe’s top takeaways
BIOCENTURY | DISCOVERY & TRANSLATIONLIVE FROM AMSTERDAM: GRAND ROUNDS EUROPE’S TOP TAKEAWAYSOskar Slotboom, Ruud Smits, and Dinko Valerio join the BioCentury team on a special edition of...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
